These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 29235882)
1. Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. Albuquerque De Almeida F; Al M; Koymans R; Caliskan K; Kerstens A; Severens JL Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):161-175. PubMed ID: 29235882 [TBL] [Abstract][Full Text] [Related]
2. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review. Di Tanna GL; Bychenkova A; O'Neill F; Wirtz HS; Miller P; Ó Hartaigh B; Globe G Pharmacoeconomics; 2019 Mar; 37(3):359-389. PubMed ID: 30596210 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management. Grustam AS; Severens JL; De Massari D; Buyukkaramikli N; Koymans R; Vrijhoef HJM Value Health; 2018 Jul; 21(7):772-782. PubMed ID: 30005749 [TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762 [TBL] [Abstract][Full Text] [Related]
5. Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review. Goehler A; Geisler BP; Manne JM; Jahn B; Conrads-Frank A; Schnell-Inderst P; Gazelle GS; Siebert U Pharmacoeconomics; 2011 Sep; 29(9):753-69. PubMed ID: 21557632 [TBL] [Abstract][Full Text] [Related]
6. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Green C Pharmacoeconomics; 2007; 25(9):735-50. PubMed ID: 17803333 [TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease. Hernandez L; Ozen A; DosSantos R; Getsios D Pharmacoeconomics; 2016 Jul; 34(7):681-707. PubMed ID: 26899832 [TBL] [Abstract][Full Text] [Related]
8. Systematic review and overview of health economic evaluation models in obesity prevention and therapy. Schwander B; Hiligsmann M; Nuijten M; Evers S Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):561-570. PubMed ID: 27570095 [TBL] [Abstract][Full Text] [Related]
9. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology. Banz K; Value Health; 2005; 8(2):128-39. PubMed ID: 15804321 [TBL] [Abstract][Full Text] [Related]
10. Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. Reed SD; Neilson MP; Gardner M; Li Y; Briggs AH; Polsky DE; Graham FL; Bowers MT; Paul SC; Granger BB; Schulman KA; Whellan DJ; Riegel B; Levy WC Am Heart J; 2015 Nov; 170(5):951-60. PubMed ID: 26542504 [TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Chhatwal J; He T; Lopez-Olivo MA Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of telehealth interventions for chronic heart failure patients: a literature review. Grustam AS; Severens JL; van Nijnatten J; Koymans R; Vrijhoef HJ Int J Technol Assess Health Care; 2014 Jan; 30(1):59-68. PubMed ID: 24495581 [TBL] [Abstract][Full Text] [Related]
13. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. Göhler A; Conrads-Frank A; Worrell SS; Geisler BP; Halpern EF; Dietz R; Anker SD; Gazelle GS; Siebert U Eur J Heart Fail; 2008 Oct; 10(10):1026-32. PubMed ID: 18760666 [TBL] [Abstract][Full Text] [Related]
15. Are adverse effects incorporated in economic models? An initial review of current practice. Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146 [TBL] [Abstract][Full Text] [Related]
16. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review. Kirsch F Value Health; 2016 Dec; 19(8):1039-1054. PubMed ID: 27987631 [TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study. Maru S; Byrnes JM; Carrington MJ; Stewart S; Scuffham PA J Med Econ; 2017 Apr; 20(4):318-327. PubMed ID: 27841726 [TBL] [Abstract][Full Text] [Related]
18. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Sculpher M; Fenwick E; Claxton K Pharmacoeconomics; 2000 May; 17(5):461-77. PubMed ID: 10977388 [TBL] [Abstract][Full Text] [Related]
19. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Cooper NJ; Sutton AJ; Abrams KR Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986 [TBL] [Abstract][Full Text] [Related]